A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1

Cas13a, an effector of type VI CRISPR-Cas systems, is an RNA guided RNase with multiplexing and therapeutic potential. This study employs the Leptotrichia shahii (Lsh) Cas13a and a repeat-based CRISPR RNA (crRNA) to track and eliminate toxic RNA aggregates in myotonic dystrophy type 1 (DM1) – a neur...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Nan, Bewick, Brittani, Xia, Guangbin, Furling, Denis, Ashizawa, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758406/
https://www.ncbi.nlm.nih.gov/pubmed/33362853
http://dx.doi.org/10.3389/fgene.2020.594576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758406/
https://www.ncbi.nlm.nih.gov/pubmed/33362853
http://dx.doi.org/10.3389/fgene.2020.594576

Ejemplares similares